Ibutamoren Magnus

Catalogue entry: Ibutamoren Magnus. Labelled content: 25 mg/tablet. Listed pack: 60 tablets. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Ibutamoren, also known as MK-677, is a nonpeptide ghrelin-receptor agonist that stimulates growth-hormone secretion. It is not a SARM. Its target is related to the pathway studied with Ipamorelin and GHRP-6, while its molecular structure and pharmacokinetics are different.

What the research measured

Nass and colleagues reported a randomised trial in healthy older adults in the Annals of Internal Medicine in 2008. They examined growth-hormone and IGF-I responses, body composition and functional measures. An increase in fat-free mass did not establish a corresponding improvement in strength or physical function. Age and study population limit extrapolation to athletes.

Sporting claims and limitations

In sporting discussions, MK-677 is associated with appetite, recovery and muscle-growth claims. The human research makes glucose regulation, insulin sensitivity, fluid retention and appetite changes relevant considerations. A higher GH or IGF-I measurement is a biological response, not proof of better sleep, stronger muscle or healthier ageing. Combined endocrine compounds add uncertainties rather than guarantee complementary effects.

Product identity and documentation

For this catalogue entry, read the selected labelled content and pack information independently of those claims. Batch documentation should distinguish MK-677 identity from a generic secretagogue description and correspond to the supplied material. A label listing a milligram amount cannot establish absorption, long-term safety or equivalence to the trial formulation.